We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+6.47%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$3.15B
AUM Growth
-$465M
Cap. Flow
-$653M
Cap. Flow %
-20.73%
Top 10 Hldgs %
68.44%
Holding
41
New
4
Increased
7
Reduced
9
Closed
8

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$94.5M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$86.4M
3
ZBH icon
Zimmer Biomet
ZBH
+$62.8M
4
MEDP icon
Medpace
MEDP
+$47.5M
5
CON
Concentra Group Holdings
CON
+$45.6M

Top Sells

Rank Stock Value
1
UHS icon
Universal Health Services
UHS
+$178M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$90.6M
3
WBA
Walgreens Boots Alliance
WBA
+$84.7M
4
HUM icon
Humana
HUM
+$71.2M
5
MYGN icon
Myriad Genetics
MYGN
+$42M

Sector Composition

Rank Sector Weight
1 Healthcare 80.29%
2 Consumer Staples 0.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$574M 18.22%
1,000,000
-750,000
-43% -$415M
ZBH icon
2
Zimmer Biomet
ZBH
$18.8B
$270M 8.57%
2,500,000
+575,000
+30% +$62.8M
MDT icon
3
Medtronic
MDT
$112B
$248M 7.86%
2,750,000
+500,000
+22% +$42.1M
BAX icon
4
Baxter International
BAX
$12.8B
$247M 7.84%
6,500,000
+1,000,000
+18% +$36.7M
VTRS icon
5
Viatris
VTRS
$20.8B
$174M 5.53%
15,000,000
– –
GMED icon
6
Globus Medical
GMED
$11.1B
$154M 4.89%
2,150,000
-350,000
-14% -$24.7M
PTCT icon
7
PTC Therapeutics
PTCT
$6.18B
$130M 4.12%
3,500,000
– –
JAZZ icon
8
Jazz Pharmaceuticals
JAZZ
$16.1B
$128M 4.07%
1,150,000
– –
GSK icon
9
GSK
GSK
$107B
$123M 3.9%
3,000,000
+325,000
+12% +$13.3M
MYGN icon
10
Myriad Genetics
MYGN
$476M
$108M 3.44%
3,950,000
-1,550,000
-28% -$42M
ASND icon
11
Ascendis Pharma A/S
ASND
$16.5B
$105M 3.32%
+700,000
New +$94.5M
SRPT icon
12
Sarepta Therapeutics
SRPT
$1.64B
$96.8M 3.07%
775,000
+625,000
+417% +$86.4M
BKD icon
13
Brookdale Senior Living
BKD
$3.55B
$94.6M 3.01%
13,935,000
-1,565,000
-10% -$11.2M
CVS icon
14
CVS Health
CVS
$135B
$94.3M 3%
1,500,000
– –
SEM
15
DELISTED
Select Medical
SEM
$74.1M 2.35%
3,944,000
-788,800
-17% -$15.1M
QGEN icon
16
Qiagen
QGEN
$8.62B
$68.4M 2.17%
1,458,333
– –
HUM icon
17
Humana
HUM
$43.9B
$63.3M 2.01%
200,000
-200,000
-50% -$71.2M
DNLI icon
18
Denali Therapeutics
DNLI
$3.79B
$58.3M 1.85%
2,000,000
– –
CON
19
Concentra Group Holdings
CON
$4.04B
$44.2M 1.4%
+1,975,000
New +$45.6M
ZIMV
20
DELISTED
ZimVie
ZIMV
$43.2M 1.37%
2,725,000
-525,000
-16% -$9.43M
MEDP icon
21
Medpace
MEDP
$16.3B
$41.7M 1.33%
+125,000
New +$47.5M
EVH icon
22
Evolent Health
EVH
$371M
$39.6M 1.26%
1,400,000
+775,000
+124% +$20M
UHS icon
23
Universal Health Services
UHS
$10.2B
$28.6M 0.91%
125,000
-825,000
-87% -$178M
BKDT
24
DELISTED
Brookdale Senior Living Inc. 7.00% Tangible Equity Units
BKDT
$23.1M 0.73%
250,000
– –
MLTX icon
25
MoonLake Immunotherapeutics
MLTX
$1.56B
$22.2M 0.71%
441,000
+86,000
+24% +$4.03M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Camber Capital Management held 41 positions worth $3.15B, down 13% from $3.61B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Camber Capital Management withdrew a net $653M in Q3 2024, closing 8 positions and reducing 9 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $90.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 70% a quarter earlier, followed by Consumer Staples.

Against the trend, Camber Capital Management opened a new position in Ascendis Pharma A/S worth $105M.

  • Camber Capital Management's largest Q3 2024 buy was Ascendis Pharma A/S: 700,000 shares worth $105M.
  • Camber Capital Management added most to Sarepta Therapeutics in Q3 2024, an estimated $86.4M increase.
  • Camber Capital Management's biggest Q3 2024 reduction was Universal Health Services, cutting an estimated $178M.
  • Camber Capital Management fully exited BioMarin Pharmaceuticals in Q3 2024, selling an estimated $90.6M.
  • Camber Capital Management's ten largest holdings make up 68% of its $3.15B portfolio in Q3 2024.
  • Camber Capital Management opened 4 new positions and closed 8 in Q3 2024.
  • Camber Capital Management's portfolio value fell 13% quarter-over-quarter to $3.15B.

Based on Camber Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.